Antimicrobial Peptides: A Plausible Approach for COVID-19 Treatment

Overview

Journal Expert Opin Drug Discov

Specialties Chemistry
Pharmacology

Date 2022 Mar 8

PMID 35255763

Authors

Pooja Rani

Bhupinder Kapoor

Monica Gulati

Atanas G Atanasov

Qushmua Alzahrani

Reena Gupta

Affiliations

Soon will be listed here.

Abstract

Introduction: Coronavirus disease 2019 (COVID-19), which emerged as a major public health threat, has affected >400 million people globally leading to >5 million mortalities to date. Treatments of COVID-19 are still to be developed as the available therapeutic approaches are not able to combat the virus causing the disease (severe acute respiratory syndrome coronavirus-2; SARS-CoV-2) satisfactorily. However, antiviral peptides (AVPs) have demonstrated prophylactic and therapeutic effects against many coronaviruses (CoVs).

Areas Covered: This review critically discusses various types of AVPs evaluated for the treatment of COVID-19 along with their mechanisms of action. Furthermore, the peptides inhibiting the entry of the virus by targeting its binding to angiotensin-converting enzyme 2 (ACE2) or integrins, fusion mechanism as well as activation of proteolytic enzymes (cathepsin L, transmembrane serine protease 2 (TMPRSS2), or furin) are also discussed.

Expert Opinion: Although extensively investigated, successful treatment of COVID-19 is still a challenge due to emergence of virus mutants. Antiviral peptides are anticipated to be blockbuster drugs for the management of this serious infection because of their formulation and therapeutic advantages. Although they may act on different pathways, AVPs having a multi-targeted approach are considered to have the upper hand in the management of this infection.

Citing Articles

The application and prospects of antimicrobial peptides in antiviral therapy.

Yang F, Ma Y Amino Acids. 2024; 56(1):68.

PMID: 39630161 PMC: 11618130. DOI: 10.1007/s00726-024-03427-0.

Recent advances in the exploration and discovery of SARS-CoV-2 inhibitory peptides from edible animal proteins.

Kong X, Wang W, Zhong Y, Wang N, Bai K, Wu Y Front Nutr. 2024; 11:1346510.

PMID: 38389797 PMC: 10883054. DOI: 10.3389/fnut.2024.1346510.

New N-Terminal Fatty-Acid-Modified Melittin Analogs with Potent Biological Activity.

Huang S, Su G, Jiang S, Chen L, Huang J, Yang F Int J Mol Sci. 2024; 25(2).

PMID: 38255940 PMC: 10815238. DOI: 10.3390/ijms25020867.

Expression of Human β-defensin 2 (hBD-2) in Pichia Pastoris and Investigation of Its Binding Efficiency with ACE-2.

Cobanoglu S, Arslan E, Yazici A, Ortucu S Protein J. 2023; 42(4):399-407.

PMID: 37291459 PMC: 10250178. DOI: 10.1007/s10930-023-10130-8.

Anti-Viral Surfaces in the Fight against the Spread of Coronaviruses.

Kwiatkowska A, Granicka L Membranes (Basel). 2023; 13(5).

PMID: 37233525 PMC: 10223398. DOI: 10.3390/membranes13050464.

References

Li F . Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol. 2016; 3(1):237-261. PMC: 5457962. DOI: 10.1146/annurev-virology-110615-042301. View

De Angelis M, Casciaro B, Genovese A, Brancaccio D, Marcocci M, Novellino E . Temporin G, an amphibian antimicrobial peptide against influenza and parainfluenza respiratory viruses: Insights into biological activity and mechanism of action. FASEB J. 2021; 35(2):e21358. DOI: 10.1096/fj.202001885RR. View

Al-Qaaneh A, Alshammari T, Aldahhan R, Aldossary H, Alkhalifah Z, Borgio J . Genome composition and genetic characterization of SARS-CoV-2. Saudi J Biol Sci. 2021; 28(3):1978-1989. PMC: 7834485. DOI: 10.1016/j.sjbs.2020.12.053. View

Zhirnov O, Klenk H, Wright P . Aprotinin and similar protease inhibitors as drugs against influenza. Antiviral Res. 2011; 92(1):27-36. DOI: 10.1016/j.antiviral.2011.07.014. View

Chew M, Poh K, Poh C . Peptides as Therapeutic Agents for Dengue Virus. Int J Med Sci. 2017; 14(13):1342-1359. PMC: 5707751. DOI: 10.7150/ijms.21875. View

Jaiswal G, Kumar V . In-silico design of a potential inhibitor of SARS-CoV-2 S protein. PLoS One. 2020; 15(10):e0240004. PMC: 7529220. DOI: 10.1371/journal.pone.0240004. View

Beddingfield B, Iwanaga N, Chapagain P, Zheng W, Roy C, Hu T . The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection. JACC Basic Transl Sci. 2020; 6(1):1-8. PMC: 7566794. DOI: 10.1016/j.jacbts.2020.10.003. View

Imran M, Saleemi M, Chen Z, Wang X, Zhou D, Li Y . Decanoyl-Arg-Val-Lys-Arg-Chloromethylketone: An Antiviral Compound That Acts against Flaviviruses through the Inhibition of Furin-Mediated prM Cleavage. Viruses. 2019; 11(11). PMC: 6893617. DOI: 10.3390/v11111011. View

Zhu Y, Yu D, Yan H, Chong H, He Y . Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity. J Virol. 2020; 94(14). PMC: 7343218. DOI: 10.1128/JVI.00635-20. View

10.

Makowski L, Olson-Sidford W, W-Weisel J . Biological and Clinical Consequences of Integrin Binding via a Rogue RGD Motif in the SARS CoV-2 Spike Protein. Viruses. 2021; 13(2). PMC: 7909284. DOI: 10.3390/v13020146. View

11.

Morgan D, Morris C, Mahindra A, Blair C, Tejeda G, Herbert I . Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalization. Pept Sci (Hoboken). 2021; 113(4):e24217. PMC: 7883042. DOI: 10.1002/pep2.24217. View

12.

Marcocci M, Amatore D, Villa S, Casciaro B, Aimola P, Franci G . The Amphibian Antimicrobial Peptide Temporin B Inhibits Herpes Simplex Virus 1 Infection. Antimicrob Agents Chemother. 2018; 62(5). PMC: 5923125. DOI: 10.1128/AAC.02367-17. View

13.

Gioia M, Ciaccio C, Calligari P, De Simone G, Sbardella D, Tundo G . Role of proteolytic enzymes in the COVID-19 infection and promising therapeutic approaches. Biochem Pharmacol. 2020; 182:114225. PMC: 7501082. DOI: 10.1016/j.bcp.2020.114225. View

14.

Odolczyk N, Marzec E, Winiewska-Szajewska M, Poznanski J, Zielenkiewicz P . Native Structure-Based Peptides as Potential Protein-Protein Interaction Inhibitors of SARS-CoV-2 Spike Protein and Human ACE2 Receptor. Molecules. 2021; 26(8). PMC: 8070189. DOI: 10.3390/molecules26082157. View

15.

Lu L, Liu Q, Zhu Y, Chan K, Qin L, Li Y . Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014; 5:3067. PMC: 7091805. DOI: 10.1038/ncomms4067. View

16.

Edwards D, Salmeron K, Lukins D, Trout A, Fraser J, Bix G . Integrin α5β1 inhibition by ATN-161 reduces neuroinflammation and is neuroprotective in ischemic stroke. J Cereb Blood Flow Metab. 2019; 40(8):1695-1708. PMC: 7370357. DOI: 10.1177/0271678X19880161. View

17.

de Loyola M, Dos Reis T, de Oliveira G, da Fonseca Palmeira J, Arganaraz G, Arganaraz E . Alpha-1-antitrypsin: A possible host protective factor against Covid-19. Rev Med Virol. 2020; 31(2):e2157. PMC: 7461031. DOI: 10.1002/rmv.2157. View

18.

Xia S, Liu M, Wang C, Xu W, Lan Q, Feng S . Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020; 30(4):343-355. PMC: 7104723. DOI: 10.1038/s41422-020-0305-x. View

19.

Gomes C, Fernandes D, Casimiro F, da Mata G, Passos M, Varela P . Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics. Front Cell Infect Microbiol. 2020; 10:589505. PMC: 7753008. DOI: 10.3389/fcimb.2020.589505. View

20.

Barh D, Tiwari S, Andrade B, Giovanetti M, Costa E, Kumavath R . Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain. F1000Res. 2020; 9:576. PMC: 7411520. DOI: 10.12688/f1000research.24074.1. View